Beltapharm SPA
⚠️ High Risk
FEI: 3009853808 • Cusano Milanino, Milan • ITALY
FEI Number
3009853808
Location
Cusano Milanino, Milan
Country
ITALYAddress
Via Stelvio 66, , Cusano Milanino, Milan, Italy
High Risk
FDA Import Risk Assessment
This firm has a significant history of FDA import refusals with notable violations.
Statistics
Score Breakdown
How is this score calculated?
Proprietary Algorithm
- 40% Violation Severity — AI-assessed (1-10)
- 30% Refusal Volume — Logarithmic scale
- 20% Recency — Decays over 5 years
- 10% Frequency — Refusals per year
© ImportRefusal.com Original Analysis
Violation Summary
UNAPPROVED
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
NOT LISTED
It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).
RX LEGEND
The article appears to be a prescription drug without a prescription drug legend as required by Section 503(b)(4).
FRNMFGREG
The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. It appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act.
LACKS N/C
The article is in package form and appears to not have a label containing an accurate statement of the quantity of the contents in terms of weight, measure or numerical count and no variations or exemptions have been prescribed by regs.
DRUG NAME
The article appears to be a drug and fails to bear the proprietary or established name and/or name and quantity of each active ingredient.
LACKS N/C
The article is subject to refusal of admission pursuant to Section 801(a)(3) of the FD&C Act in that it appears to be misbranded within the meaning of Section 403(e)(2) of the FD&C Act in that the food is in package form and the label fails to bear an accurate statement of the quantity of the contents in terms of weight, measure, or numerical count in accordance with Section 403(e)(2) of the FD&C Act.
DIRECTIONS
The article is subject to refusal of admission pursuant to section 801(a)(3) in that it is a device whose label appears to not bear adequate directions for use.
Refusal History
| Date | Product | Violations | Division |
|---|---|---|---|
| 1/23/2024 | 66VDJ99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Division of Northeast Imports (DNEI) |
| 10/22/2021 | 66VDJ99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Division of Northeast Imports (DNEI) |
| 4/20/2018 | 64LCJ67CLOBETASOL PROPIONATE (GLUCOCORTICOID) | Division of Northeast Imports (DNEI) | |
| 3/23/2017 | 61GDK57SULFAMETHOXAZOLE (ANTI-BACTERIAL) (NOT ANTIBIOTIC) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/23/2017 | 60WDA18NICLOSAMIDE (ANTHELMINTIC) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/23/2017 | 56GCA50NYSTATIN (ANTIFUNGAL) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/23/2017 | 56DCO41NEOMYCIN SULFATE (AMINOGLYCOSIDES) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/23/2017 | 61GDK57SULFAMETHOXAZOLE (ANTI-BACTERIAL) (NOT ANTIBIOTIC) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/23/2017 | 61WCA18MICONAZOLE NITRATE (ANTI-FUNGAL) (NOT ANTIBIOTIC) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/23/2017 | 56DCO41NEOMYCIN SULFATE (AMINOGLYCOSIDES) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/23/2017 | 60WCA01ALBENDAZOLE (ANTHELMINTIC) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/23/2017 | 56DCO41NEOMYCIN SULFATE (AMINOGLYCOSIDES) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/23/2017 | 56DCO41NEOMYCIN SULFATE (AMINOGLYCOSIDES) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/23/2017 | 61WCA18MICONAZOLE NITRATE (ANTI-FUNGAL) (NOT ANTIBIOTIC) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/23/2017 | 61WCA04CLOTRIMAZOLE (ANTI-FUNGAL) (NOT ANTIBIOTIC) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/23/2017 | 56GCA50NYSTATIN (ANTIFUNGAL) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/23/2017 | 56DCO41NEOMYCIN SULFATE (AMINOGLYCOSIDES) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/23/2017 | 56DCO41NEOMYCIN SULFATE (AMINOGLYCOSIDES) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/23/2017 | 56GCA50NYSTATIN (ANTIFUNGAL) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/23/2017 | 56DCO41NEOMYCIN SULFATE (AMINOGLYCOSIDES) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/23/2017 | 61GDK57SULFAMETHOXAZOLE (ANTI-BACTERIAL) (NOT ANTIBIOTIC) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/23/2017 | 60TCA05CIMETIDINE (ANTAGONIST) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/21/2017 | 60WCA01ALBENDAZOLE (ANTHELMINTIC) | New Orleans District Office (NOL-DO) | |
| 3/21/2017 | 56ICK10ERYTHROMYCIN (MACROLIDES) | New Orleans District Office (NOL-DO) | |
| 3/21/2017 | 61GDK57SULFAMETHOXAZOLE (ANTI-BACTERIAL) (NOT ANTIBIOTIC) | New Orleans District Office (NOL-DO) | |
| 3/21/2017 | 66BDO25ETHAMIVAN (STIMULANT) | New Orleans District Office (NOL-DO) | |
| 3/21/2017 | 60TCA05CIMETIDINE (ANTAGONIST) | New Orleans District Office (NOL-DO) | |
| 3/21/2017 | 61GDK57SULFAMETHOXAZOLE (ANTI-BACTERIAL) (NOT ANTIBIOTIC) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/21/2017 | 60TCA05CIMETIDINE (ANTAGONIST) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/21/2017 | 56DCO41NEOMYCIN SULFATE (AMINOGLYCOSIDES) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/21/2017 | 56DCO41NEOMYCIN SULFATE (AMINOGLYCOSIDES) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/21/2017 | 61WCJ99A-FUNGAL N.E.C. | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/21/2017 | 61WCA18MICONAZOLE NITRATE (ANTI-FUNGAL) (NOT ANTIBIOTIC) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/21/2017 | 61WCA04CLOTRIMAZOLE (ANTI-FUNGAL) (NOT ANTIBIOTIC) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/21/2017 | 60TCA05CIMETIDINE (ANTAGONIST) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 12/2/2015 | 61WCY04CLOTRIMAZOLE (ANTI-FUNGAL) (NOT ANTIBIOTIC) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 1/6/2015 | 64LDJ67CLOBETASOL PROPIONATE (GLUCOCORTICOID) | Baltimore District Office (BLT-DO) | |
| 9/4/2014 | 66YCC99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | Division of Northeast Imports (DNEI) | |
| 9/8/2010 | 64LCO67CLOBETASOL PROPIONATE (GLUCOCORTICOID) | Southwest Import District Office (SWI-DO) | |
| 9/2/2009 | 64LCJ99GLUCOCORTICOID N.E.C. | 75UNAPPROVED | New York District Office (NYK-DO) |
| 9/2/2009 | 64LCJ99GLUCOCORTICOID N.E.C. | 75UNAPPROVED | New York District Office (NYK-DO) |
| 11/18/2008 | 64LBJ67CLOBETASOL PROPIONATE (GLUCOCORTICOID) | 75UNAPPROVED | Southwest Import District Office (SWI-DO) |
| 8/5/2008 | 64LAJ67CLOBETASOL PROPIONATE (GLUCOCORTICOID) | Los Angeles District Office (LOS-DO) | |
| 8/5/2008 | 64LDJ06BETAMETHASONE DIPROPIONATE (GLUCOCORTICOID) | 75UNAPPROVED | Los Angeles District Office (LOS-DO) |
| 4/24/2007 | 61WCA04CLOTRIMAZOLE (ANTI-FUNGAL) (NOT ANTIBIOTIC) | New Orleans District Office (NOL-DO) | |
| 4/24/2007 | 56ECO80TETRACYCLINE (TETRACYCLINES) | New Orleans District Office (NOL-DO) | |
| 4/24/2007 | 56GCA50NYSTATIN (ANTIFUNGAL) | New Orleans District Office (NOL-DO) | |
| 4/24/2007 | 60WCA01ALBENDAZOLE (ANTHELMINTIC) | New Orleans District Office (NOL-DO) | |
| 4/24/2007 | 60WCA01ALBENDAZOLE (ANTHELMINTIC) | New Orleans District Office (NOL-DO) | |
| 4/24/2007 | 62WCO09ZINC OXIDE ASTRINGENT/ANTI-PERSPIRANT) | 118NOT LISTED | New Orleans District Office (NOL-DO) |
| 5/5/2006 | 66VBY99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Southwest Import District Office (SWI-DO) |
| 5/5/2006 | 66VBY99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Southwest Import District Office (SWI-DO) |
| 3/22/2006 | 64LCJ67CLOBETASOL PROPIONATE (GLUCOCORTICOID) | New Orleans District Office (NOL-DO) | |
| 3/22/2006 | 64LCJ06BETAMETHASONE DIPROPIONATE (GLUCOCORTICOID) | New Orleans District Office (NOL-DO) | |
| 3/23/2005 | 64LCJ67CLOBETASOL PROPIONATE (GLUCOCORTICOID) | New York District Office (NYK-DO) | |
| 4/14/2004 | 64LDJ67CLOBETASOL PROPIONATE (GLUCOCORTICOID) | New York District Office (NYK-DO) | |
| 12/30/2003 | 64LDO28FLUOCINONIDE (GLUCOCORTICOID) | 75UNAPPROVED | Los Angeles District Office (LOS-DO) |
| 12/10/2003 | 66VBJ99MISCELLANEOUS PATENT MEDICINES, ETC. | New York District Office (NYK-DO) | |
| 10/23/2003 | 64LCJ67CLOBETASOL PROPIONATE (GLUCOCORTICOID) | 75UNAPPROVED | Southwest Import District Office (SWI-DO) |
| 1/4/2002 | 66BIY99STIMULANT N.E.C. | 75UNAPPROVED | Southwest Import District Office (SWI-DO) |
| 1/4/2002 | 66BIY99STIMULANT N.E.C. | 75UNAPPROVED | Southwest Import District Office (SWI-DO) |
| 1/4/2002 | 66BIY99STIMULANT N.E.C. | 75UNAPPROVED | Southwest Import District Office (SWI-DO) |
Frequently Asked Questions
What is Beltapharm SPA's FDA import refusal history?
Beltapharm SPA (FEI: 3009853808) has 62 FDA import refusal record(s) in our database, spanning from 1/4/2002 to 1/23/2024.
What is an FEI number?
FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. Beltapharm SPA's FEI number is 3009853808.
What types of violations has Beltapharm SPA received?
Beltapharm SPA has been cited for 8 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.
Where does this information about Beltapharm SPA come from?
All FDA import refusal data for Beltapharm SPA is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.
Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.